Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement.
Ontology highlight
ABSTRACT: The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib-resistant patients, as may provide much longer overall survival than previously reported treatments.
SUBMITTER: Espanol I
PROVIDER: S-EPMC5538069 | biostudies-other | 2017 Aug
REPOSITORIES: biostudies-other
ACCESS DATA